Literature DB >> 6238730

Usefulness of 4-methylumbelliferyl-6-sulfo-2-acetamido-2-deoxy-beta-D-glucopyrano sid e for the diagnosis of GM2 gangliosidoses in leukocytes.

K Inui, D A Wenger.   

Abstract

4-Methylumbelliferyl-6-sulfo-2-acetamido-2-deoxy-beta-D-glucopyranoside was synthesized and tested as a substrate for the diagnosis of GM2 gangliosidoses using leukocytes. Less than 2% of normal activity was measured in homogenates from patients with typical Tay-Sachs disease and from a patient with a variant form having 37% Hexosaminidase A by heat denaturation using the usual fluorogenic substrate. An adult patient had 8.5% of normal activity. Three patients with Sandhoff disease were found to have values ranging from 17% to 37% of normal. These values overlap the range found for carriers of Tay-Sachs disease, and suggest that the usefulness of this substrate, while excellent for diagnosing B variants of GM2 gangliosidosis, requires further study. Perhaps when used together with 4-methylumbelliferyl-2-acetamido-2-deoxy-beta-D-glucopyranoside excellent discriminations of patients, carriers and controls will be realized.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6238730     DOI: 10.1111/j.1399-0004.1984.tb01066.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  11 in total

1.  G(M2)-ganglioside metabolism in situ in mucolipidosis IV fibroblasts.

Authors:  S Raghavan; E Leshinsky; E H Kolodny
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

2.  Towards quality assurance in the determination of lysosomal enzymes: a two-centre study.

Authors:  Z Lukacs; A Keil; V Peters; A Kohlschütter; G F Hoffmann; M Cantz; J Kopitz
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

3.  External quality assurance programme for enzymatic analysis of lysosomal storage diseases: a pilot study.

Authors:  G J G Ruijter; M Boer; C W Weykamp; R de Vries; I van den Berg; J Janssens-Puister; K Niezen-Koning; R A Wevers; B J H M Poorthuis; O P van Diggelen
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

4.  Diagnosis and carrier detection of Tay-Sachs disease: direct determination of hexosaminidase A using 4-methylumbelliferyl derivatives of beta-N-acetylglucosamine-6-sulfate and beta-N-acetylgalactosamine-6-sulfate.

Authors:  Y Ben-Yoseph; J E Reid; B Shapiro; H L Nadler
Journal:  Am J Hum Genet       Date:  1985-07       Impact factor: 11.025

5.  Clinical,biochemical and molecular analysis of five Chinese patients with Sandhoff disease.

Authors:  Wen Zhang; Huasong Zeng; Yonglan Huang; Ting Xie; Jipeng Zheng; Xiaoyuan Zhao; Huiying Sheng; Hongsheng Liu; Li Liu
Journal:  Metab Brain Dis       Date:  2016-03-28       Impact factor: 3.584

6.  Intermediate forms of human beta-N-acetylhexosaminidase lack activity towards 4-methylumbelliferyl beta-N-acetylglucosaminide 6-sulphate.

Authors:  T Beccari; C Emiliani; R Hosseini; A Orlacchio; J L Stirling
Journal:  Biochem J       Date:  1987-06-15       Impact factor: 3.857

7.  Hexosaminidase A activity in skin fibroblasts from various types of GM2 gangliosidosis using a fluorogenic sulphated substrate.

Authors:  K Inui; T Yutaka; S Okada; H Yabuuchi; D A Wenger; R J Desnick
Journal:  J Inherit Metab Dis       Date:  1985       Impact factor: 4.982

8.  Identification of GM2-gangliosidosis B1 variant carriers.

Authors:  M G Ribeiro; R Pinto; P Oliveira; M C Sá Miranda
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

9.  GM2-ganglioside metabolism in hexosaminidase A deficiency states: determination in situ using labeled GM2 added to fibroblast cultures.

Authors:  S S Raghavan; A Krusell; J Krusell; T A Lyerla; E H Kolodny
Journal:  Am J Hum Genet       Date:  1985-11       Impact factor: 11.025

10.  Early and severe sensory loss in three adult siblings with hexosaminidase A and B deficiency (Sandhoff disease).

Authors:  H Schnorf; R Gitzelmann; N U Bosshard; M Spycher; W Waespe
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-11       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.